Trial record 6 of 71 for:    vitamin D asthma

Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2016 by University of Pittsburgh
Sponsor:
Collaborators:
Pharmavite
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Juan Celedon, MD, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT02687815
First received: February 11, 2016
Last updated: February 29, 2016
Last verified: February 2016
  Purpose
This study will determine whether vitamin D3 prevents severe asthma attacks in children who have a serum vitamin D (25(OH)D) level <30 ng/ml and who are being treated with inhaled corticosteroids for asthma. Half the participants will receive vitamin D3 at a dose of 4,000 IU/day, and the other half will receive placebo.

Condition Intervention Phase
Asthma
Drug: vitamin D3 4000 IU
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Vitamin D to Prevent Severe Asthma Exacerbations

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Severe asthma exacerbations [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

    A severe asthma exacerbation is defined as an exacerbation that meets either of these criteria: 1) Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days OR

    2) A hospitalization or ER visit because of asthma, requiring systemic corticosteroids.



Secondary Outcome Measures:
  • Severe asthma exacerbations resulting from viral infections [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    A severe viral asthma exacerbation is defined as a severe asthma exacerbation (defined above) along with a positive respiratory viral panel from a nasal blow collected within 72 hours of the exacerbation.

  • Reduction in ICS dose at visit 6 [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

    In the absence of moderate or severe asthma exacerbations, participants may have their dose of ICS reduced by 50% if the following criteria are met at visit 6 (halfway through the Trial Phase):

    • ACT score greater than 19
    • Both pre-bronchodilator FEV1 and FEV1/FVC ≥80% of predicted
    • Use of ≤4 puffs of a rescue inhaler per week
    • ≤1 day per month with asthma symptoms preventing full participation in usual daily activities
    • Clinician's judgment regarding adequate asthma control

  • Average cumulative prescribed dose of ICS at the end of the trial [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: February 2016
Estimated Study Completion Date: September 2019
Estimated Primary Completion Date: September 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: vitamin D3
Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
Drug: vitamin D3 4000 IU
The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
Other Name: Cholecalciferol
Placebo Comparator: placebo
placebo formulations will be in gel cap form and identical to the active drug
Drug: Placebo
The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.

Detailed Description:

Results from experimental studies, observational studies, and two small trials suggest that vitamin D reduces the risk of severe asthma exacerbations, and that this protective effect may be due to immune modulation of viral illnesses and/or increased response to inhaled corticosteroids (ICS).

On the basis of those findings, the investigators hypothesize that vitamin D reduces the incidence of severe asthma exacerbations in high-risk school-aged children who have a serum vitamin D level <30 ng/ml and who are being treated with ICS for persistent asthma. The investigators further hypothesize that this protective effect results from reduced incidence of common viral illnesses or enhanced response to ICS. These hypotheses will be tested in a 48-week randomized double-masked placebo-controlled trial of vitamin D3 supplementation to prevent severe asthma exacerbations in 400 children aged 6 to 14 years who have vitamin D insufficiency or deficiency (a serum 25(OH)D <30 ng/ml) and experienced a severe exacerbation in the prior year (a marker of high risk for subsequent events), and who (after a run-in period) are well controlled on medium-dose inhaled corticosteroids.

Our primary aim will determine whether vitamin D3 (4,000 IU/day) reduces the risk of severe asthma exacerbations (our primary outcome) in participating children. Secondary aims will determine the efficacy of vitamin D3 supplementation in: 1) preventing severe asthma exacerbations due to viral infections, 2) reducing the daily and average cumulative dose of inhaled corticosteroids.

  Eligibility

Ages Eligible for Study:   6 Years to 14 Years   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 6 to 14 years old
  • Physician-diagnosed asthma for at least one year
  • At least one severe asthma exacerbation in the previous year
  • Use of asthma medications (daily controller medication [ICS or leukotriene inhibitor] or inhaled β2-agonist [at least three days per week]) for at least six months in the previous year
  • Vitamin D insufficiency (i.e., serum vitamin D (25(OH)D level <30 ng/ml (75 nmol/L))
  • FEV1 ≥70 % of predicted
  • Positive bronchodilator response (i.e., increase in FEV1 ≥8% from baseline after inhaled short acting beta agonist or increased airway responsiveness to methacholine (PC20 ≤8 mg/ml if not on ICS or PC20 ≤16 mg/ml if on ICS)
  • Study protocol (i.e., age-appropriate dose of Fluticasone and no other asthma controller medications) approved by the child's regular doctor
  • Parental consent and child's assent to participate in the study.

Additional inclusion criteria applied after the run-in period, to be eligible for randomization:

  • Adherence with ICS and study medication (≥75% use [at least 21 of 28 days]) during the run-in period
  • Willingness to be randomized and complete study

Exclusion Criteria:

  • Serum calcium >10.8 mg/dl
  • Serum 25(OH) D <10 ng/ml (25 nmol/L)
  • Chronic respiratory disorder other than asthma
  • Severe asthma (intubation for asthma at any time OR ≥3 hospitalizations for asthma in previous year OR ≥6 severe asthma exacerbations in previous year)
  • Hepatic/renal disease, rickets, malabsorption, or other diseases that would affect vitamin D metabolism
  • Current smoking, or former smoking if ≥5 pack-years
  • Immune deficiency, cleft palate or Down's syndrome
  • Treatment with anticonvulsants or ≥1,000 IU/day of vitamin D2 or D3
  • Chronic oral corticosteroid therapy
  • Inability to perform acceptable spirometry
  • Use of investigational therapies or participation in trials 30 days before or during the study
  • Participant is currently breast feeding an infant
  • Pregnancy
  • Weight less than 10 kg
  • Plans to move out of the study site (Pittsburgh or San Francisco) area in the next year

Additional exclusion criteria applied after the run-in period:

  • Any severe asthma exacerbation during the run-in period
  • Need for asthma medications other than ICS and p.r.n. rescue inhalers during the run-in period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02687815

Contacts
Contact: Elizabeth Hartigan, RN 412-692-7060 elizabeth.hartigan@chp.edu
Contact: Cynthia Granny 412-692-7041 cynthia.granny@chp.edu

Locations
United States, California
University of California - San Francisco Recruiting
San Francisco, California, United States, 94102
Principal Investigator: Michael Cabana         
United States, Pennsylvania
Children's Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Principal Investigator: Juan C Celedon, MD, DrPH         
Sponsors and Collaborators
University of Pittsburgh
Pharmavite
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Principal Investigator: Juan C. Celedón, MD, DrPH University of Pittsburgh
Principal Investigator: Stephen Wisniewski, PhD University of Pittsburgh
  More Information

Responsible Party: Juan Celedon, MD, Niels K. Jerne Professor of Pediatrics, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02687815     History of Changes
Other Study ID Numbers: PRO12020541  U01HL119952 
Study First Received: February 11, 2016
Last Updated: February 29, 2016
Health Authority: United States: Food and Drug Administration
United States: Federal Government
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by University of Pittsburgh:
Vitamin D, severe asthma exacerbations, children

Additional relevant MeSH terms:
Asthma
Vitamins
Vitamin D
Ergocalciferols
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on August 29, 2016